3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Pancreatic Neoplasms
26
Urinary Bladder Neoplasms
17
Carcinoma, Non-Small-Cell Lung
17
Lung Neoplasms
13
Ovarian Neoplasms
10
Nasopharyngeal Carcinoma
9
Biliary Tract Neoplasms
8
Non-Muscle Invasive Bladder Neoplasms
7
Neoplasm Metastasis
7
Cholangiocarcinoma
7
Lymphoma, Large B-Cell, Diffuse
6
Triple Negative Breast Neoplasms
5
Colorectal Neoplasms
5
Breast Neoplasms
5
Recurrence
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Neoplasms
4
Fallopian Tube Neoplasms
4
Endometrial Neoplasms
4
Carcinoma, Transitional Cell
4
Osteosarcoma
3
Melanoma
3
Lymphoma, Non-Hodgkin
3
Uterine Cervical Neoplasms
2
Urologic Neoplasms
2
Rectal Neoplasms
2
Lymphoma, Follicular
2
Lymphoma, B-Cell
2
Gallbladder Neoplasms
2
Colonic Neoplasms
2
Interventions
mirvetuximab soravtansine
1
liposomal doxorubicin
1
Paclitaxel
1
Gemcitabine
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
×
Gemcitabine
×
30 days
×
Clear all
NCT04274426
2026-05-13
MIROVA
AGO Research GmbH
Phase 2
Active not recruiting
136 enrolled